The American Society of Clinical Oncology (ASCO®) and Conexiant today announced the launch of ASCO AI in Oncology, a premier digital destination designed to help oncology professionals navigate the transformative role of artificial intelligence (AI) in cancer care. Launching this initiative marks the second major collaboration between the two organizations, following the long-standing success of The ASCO Post, established in 2010.
As AI technologies rapidly change medical practice, ASCO AI in Oncology serves as an educational platform for trusted research and up-to-date information to help providers remain prepared and confident.
ASCO AI in Oncology planned content pillars:
- Trusted Intelligence: Curated, expert-led insights from authoritative sources, prioritizing clinical relevance.
- Practical Education: Focused content on how AI tools can enhance diagnostic accuracy, streamline workflows, and personalize treatment pathways.
- Community Perspective: A collaborative environment where global oncology clinicians and researchers can connect across disciplines and institutions to share real-world implementation experiences.
In addition to deep-dive clinical analyses, the platform will feature practitioner-submitted commentaries and interactive programs designed to advance professional development. Collectively, these tools are designed to help clinicians leverage AI for clinical success.
“AI is transforming cancer care at an incredible rate, but the amount of noise in the AI space can be distracting or confusing. This resource cuts through that noise by delivering useful insights directly from trusted oncology experts,” said ASCO Chief Executive Officer Clifford Hudis, MD, FACP, FASCO. “Translating these insights into practical tips can help clinicians confidently use AI to prioritize what matters most: patient outcomes.”
The collaboration with Conexiant signifies another major step in ASCO’s broader initiative to responsibly harness the capabilities of AI to support oncology professionals and improve cancer care.
